secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K/A
Filed at:   2026-09-02T20:08:23+00:00
Accession:  0000886163-26-000048
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand files XOMA Royalty financials post-merger; acquired firm lost $41.2M in H1 2026
--------------------------------------------------------------------------------

- Merger with XOMA Royalty closed; deal agreement dated April 27, 2026, amended May 16, 2026.
- XOMA Royalty H1 2026 (unaudited): net loss $41.2M, total assets $244.3M, accumulated deficit $1.26B.
- H1 2026 charges: $23.6M impairment, $19.7M credit losses on purchased receivables; income/revenues $29.3M.
- Cash, equivalents, and restricted cash $150.6M at June 30, 2026; liquidity assessed sufficient for at least one year.
- Pro forma combined financial statements filed for periods ended June 30, 2026 and December 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000048/0000886163-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000048/lgnd-20260714.htm
  HTML page:      https://secwatch.observer/filing/0000886163-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer